Yesterday, 339 patient, provider, and caregiver groups, on behalf of the Part B Access for Seniors and Physicians Coalition, sent a letter to Congress encouraging lawmakers to block the implementation of the International Pricing Index (IPI) model that was announced last month.
Yesterday, 339 patient, provider, and caregiver groups, on behalf of the Part B Access for Seniors and Physicians Coalition (ASP Coalition), sent a letter to Congress encouraging lawmakers to block the implementation of the International Pricing Index (IPI) model that was announced last month.
The letter, addressed to Senate Majority Leader Mitch McConnell, R-Kentucky, Senate Minority Leader Chuck Schumer, D-New York, House Speaker Paul Ryan, R-Wisconsin, and House Minority Leader Nancy Pelosi, D-California, explained that the groups “support efforts to strengthen the United States’ healthcare system through patient-centered reforms that embrace competition, foster the provider-patient relationship, and value transformation.” According to the groups, which include the Association of Community Cancer Centers, the Coalition of State Rheumatology Organizations, the Community Oncology Alliance, and the Global Healthy Living Foundation, the IPI is not aligned with those principles.
The IPI proposal would allow CMS to implement its reference price structure over a 5-year period, from 2020-2025, which would allow Medicare to more closely align its payment amount for selected Part B drugs with prices paid in other nations, as well as allow for the private-sector negotiations of drugs. CMS believes that the proposal could generate 30% in cost savings, though this figure does not take into account the prices of biosimilars; instead, it only compares the prices of reference products.
“Our greatest concern is that this model would impose decisions made in countries such as Greece or Japan on approximately half of all independent physicians and hospital providers, as well as their patients,” read the letter. “Compounding these concerns, the model also interjects new middlemen between physicians and patients—vendors that would impose requirements dictating treatment for patients with cancer, autoimmune disorders, and other complex, life-threatening conditions.”
The groups went on to warn Congress that this pricing model sets a risky precedent for other healthcare providers and services, because once Medicare takes on foreign price controls, CMS could then apply the same principles to other services. The letter also takes issue with the fact that the proposed model would enlist vendors with little to no clinical or medical expertise as the middlemen between patients and doctors.
“We support use of the Center for Medicare and Medicaid Innovation to test patient-centered, voluntary, small-scale reforms that can be fully evaluated. However, the IPI model is a wide-scale demonstration that would be mandatory, affecting 50% of physicians and hospitals serving Medicare Part B beneficiaries,” read the letter.
The groups emphasized that there are currently over 59 million seniors and persons with disabilities who rely on Medicare Part B for essential treatments. Due to this fact, any changes should be tested in a limited and thoughtful way, “based on clinical evidence and guidelines focused on high-quality care.” In closing, the letter urged Congress to work with the 339 organizations to help seek workable solutions focused on patients and providers.
CMS will continue to take comments on the IPI model until December 31, 2018.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.